The Food and Drug Administration (FDA) approved the use of the drug gefapixant for the treatment of chronic cough.
Gefapixant was developed by Merck and has undergone several clinical trials.  In one study, the drug reduced cough frequency by 60%.
The drug has some mild side effects such as nausea and dizziness.  Merck plans to file additional applications in Europe.
